NCIt definition : A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab
contains two antigen-recognition sites: one for human CD3, a T cell surface antigen,
and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed
on B-cells during most stages of B-cell development and is often overexpressed in
B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing
B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic
T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.;